small molecules for protein misfolding
 

http://www.genengnews.com/gen-news-h...ases/81245205/

Elan is making a $20 million equity investment in U.S. firm Proteostasis Therapeutics as part of a drug discovery partnership focused on neurodegenerative and dementia-related disorders including Parkinson disease, Huntington disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer disease. ..

Proteostasis is developing a class of small molecule therapeutics known as proteostasis regulators for treating neurodegenerative, metabolic, genetic, and inflammatory disorders. The candidates are designed to correct perturbed signalling pathways in disease, and restore the correct interaction of the network of proteins controlled by known biological signalling pathways and processes that control protein folding, trafficking, and clearance, which are collectively known as the proteostasis network.